Yescarta is a revolutionary new cancer therapy that has revolutionized how cancer is treated. Developed by the pharmaceutical company Kite Pharma, Yescarta is a form of chimeric antigen receptor T-cell (CAR-T) therapy that has been approved by the FDA to treat non-Hodgkin lymphoma and certain types of large B-cell lymphoma. In this article, we will explore who makes Yescarta, how it works, and what the future holds for this innovative form of cancer treatment.
Yescarta is a chimeric antigen receptor (CAR) T cell therapy developed by Kite Pharma, a Gilead Company. CAR T cell therapies are used to treat certain types of blood cancers and work by extracting T cells from the patient’s blood, programming them to recognize and attack cancer cells, and then infusing them back into the patient. Yescarta was approved by the U.S. Food and Drug Administration (FDA) in 2017 and is now used to treat adults with certain kinds of large B-cell lymphoma.
What is Yescarta?
Yescarta is an innovative cancer immunotherapy developed by Kite Pharma, a Gilead Company. It is a genetically modified version of the patient’s own T-cells, designed to recognize and attack cancer cells. Yescarta is the first FDA-approved gene therapy for non-Hodgkin’s lymphoma.
Who Makes Yescarta?
Yescarta is developed and marketed by Kite Pharma, a Gilead Company. Kite Pharma is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapies. Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing and commercializing therapies for serious and life-threatening diseases.
How Does Yescarta Work?
Yescarta is a gene therapy that uses the patient’s own T-cells to target and kill cancer cells. It is a genetically modified version of the patient’s own T-cells that are specifically designed to recognize and attack cancer cells. The T-cells are removed from the patient’s blood, genetically modified to express a chimeric antigen receptor (CAR) that targets a specific protein found on the surface of the cancer cells, and then re-infused back into the patient’s bloodstream. Once the modified T-cells are in the bloodstream, they recognize and attack the cancer cells.
What Conditions Does Yescarta Treat?
Yescarta is approved by the FDA to treat adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. It is specifically indicated for the treatment of diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and high-grade B-cell lymphoma (HGBL).
Few Frequently Asked Questions
Who Makes Yescarta?
Answer: Yescarta is a chimeric antigen receptor T-cell (CAR-T) therapy developed by Kite Pharma and marketed by Gilead Sciences. Kite Pharma is a biotechnology company specializing in the research and development of engineered autologous cell therapies for the treatment of cancer. Gilead Sciences is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel therapeutics.
What is Yescarta?
Answer: Yescarta is a chimeric antigen receptor T-cell (CAR-T) therapy. It is an immunotherapy used to treat certain types of non-Hodgkin lymphoma and mantle cell lymphoma. CAR-T therapies are created by taking T cells from a patient’s blood and engineering them to express a specific type of protein, called a chimeric antigen receptor (CAR). The CAR helps the T cells recognize and attack cancer cells.
What is the Cost of Yescarta?
Answer: The cost of Yescarta is approximately $373,000 for a single treatment, which is the highest priced cancer therapy on the market. This cost includes the cost of the drug itself and all associated services, such as hospitalization and medical monitoring. The cost of the drug is based on its efficacy and the expected benefit to patients.
How Does Yescarta Work?
Answer: Yescarta works by taking T cells from a patient’s blood and engineering them to express a chimeric antigen receptor (CAR). The CAR helps the T cells recognize and attack cancer cells. The CAR-T cells are then infused back into the patient, where they can recognize and attack cancer cells. This targeted attack helps to reduce the size of the cancer and slow its growth.
What Types of Cancer Can Yescarta Treat?
Answer: Yescarta is approved for the treatment of certain types of non-Hodgkin lymphoma and mantle cell lymphoma. It is not approved for other types of cancer and is not a cure for cancer.
What are the Side Effects of Yescarta?
Answer: The most common side effects of Yescarta are fever, chills, fatigue, nausea, and low blood pressure. Other side effects may include headache, diarrhea, rash, shortness of breath, and infection. Some patients may also experience severe side effects, such as cytokine release syndrome and neurotoxicity. It is important to discuss potential side effects with a healthcare provider before starting treatment.
Yescarta is a revolutionary gene therapy developed by Kite Pharma to treat certain types of non-Hodgkin’s lymphoma. With the help of the latest advancements in biotechnology, Yescarta has proven to be a safe and effective treatment option for many cancer patients. Kite Pharma’s team of dedicated researchers, scientists, and clinicians have worked tirelessly to bring Yescarta to market and make it accessible to those in need. Through their commitment to providing cutting-edge treatments, Kite Pharma has shown that it is at the forefront of the fight against cancer.